ClinicalTrials.gg
CompletedNCT00522873Updated Dec 31, 2014Results posted

Endometrial Safety Study

A Phase 3 interventional study of 0.25mg DRSP / 0.5mg E2 (BAY86-4891) and 0.5mg NETA / 1.0mg E2 (Activella) in Postmenopause, sponsored by Bayer. Completed at 59 sites in 8 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-12-31.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
662
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.

Enrollment
4th of 13
662 · median 431
Started
2007
with 3 others
Phase 3
8 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
4 of 13
Bayer

Among the 13 studies testing estradiol in Hot Flashes, this one is the 4th largest by enrollment, is one of 4 that started in 2007, is one of 8 in phase 3, and was the 7th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About estradiol

Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing estradiol in Hot Flashes as a file.
02

Study summary

The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).

03

Conditions studied

  • Postmenopause

Browse trials for

Keywords

  • Postmenopausal Symptoms e.g.
  • Hot flushes
  • Sweating episodes
  • Vaginal dryness
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women between 40 and 65 years of age with hormone therapy indication (symptoms and need for treatment)
  • Non-hysterectomized women.

Exclusion criteria

Exclusion Criteria:

  • Usual exclusion criteria for hormone therapy apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
662 participants (actual)

Study arms

  • Experimental
    0.25mg DRSP / 0.5mg E2 (BAY86-4891)

    One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).

    Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)

  • Active comparator
    0.5mg NETA / 1.0mg E2 (Activella)

    One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).

    Drug: 0.5mg NETA / 1.0mg E2 (Activella)

Interventions

  • Drug0.25mg DRSP / 0.5mg E2 (BAY86-4891)

    Drug pages: Drospirenone · Estradiol

    One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).

  • Drug0.5mg NETA / 1.0mg E2 (Activella)

    One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).

06

What researchers measure

Primary outcomes

  1. Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment)

    The number of women who had a biopsy classified as 'hyperplasia or worse' at any time during the study. According to the protocol this endpoint was defined as primary for the DRSP/E2 group only.

    Time frame: Up to one year

Secondary outcomes

  1. Number of Participants With Amenorrhea During Month 1 to 3 of Treatment

    The women were to record daily in a diary, indicating 'no bleeding', 'spotting', 'light bleeding', 'normal bleeding' or 'heavy bleeding'. Women were considered to have amenorrhea if they had no bleeding and no spotting day within the given time interval.

    Time frame: Month 1 to Month 3

  2. Number of Participants With Amenorrhea During Month 10 to 12 of Treatment

    The women were to record any bleeding daily in a diary, indicating 'no bleeding', 'spotting', 'light bleeding', 'normal bleeding' or 'heavy bleeding'. Women were considered to have amenorrhea if they had no bleeding and no spotting day within the given time interval.

    Time frame: Month 10 to Month 12

07

Results

Posted Jun 28, 2012

Participant flow

Only non-hysterectomized, postmenopausal women could take part in this study. The women had to have symptoms requiring hormone therapy in the opinion of the investigator. An endometrial biopsy at screening was to show no evidence of endometrial hyperplasia or cancer.

Participant flow — Overall Study
Milestone0.25mg DRSP / 0.5mg E2 (BAY86-4891)0.5mg NETA / 1.0mg E2 (Activella)
Started490172
Received treatment489172
Completed394128
Not completed9644
Withdrew: Adverse event4126
Withdrew: Withdrawal by subject209
Withdrew: Protocol violation144
Withdrew: Lost to follow-up113
Withdrew: Personal reasons81
Withdrew: Medication errors11
Withdrew: Never received medication10

Outcome measures

PrimaryNumber of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment)

The number of women who had a biopsy classified as 'hyperplasia or worse' at any time during the study. According to the protocol this endpoint was defined as primary for the DRSP/E2 group only.

Time frame:
Up to one year
Reported as:
Number · Participants
Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment)
Participants0.25mg DRSP / 0.5mg E2 (BAY86-4891)
Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment)0
Statistical analysis
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) · Proportion: 0.0000 · 95% CI 0.0000 to 0.0119The number of women who had a biopsy classified as 'hyperplasia or worse' was divided by the number of women with an evaluable biopsy (i.e. classified as 'normal' after 1 year of treatment or as 'hyperplasia or worse' at any time during the study).
SecondaryNumber of Participants With Amenorrhea During Month 1 to 3 of Treatment

The women were to record daily in a diary, indicating 'no bleeding', 'spotting', 'light bleeding', 'normal bleeding' or 'heavy bleeding'. Women were considered to have amenorrhea if they had no bleeding and no spotting day within the given time interval.

Time frame:
Month 1 to Month 3
Reported as:
Number · Participants
Number of Participants With Amenorrhea During Month 1 to 3 of Treatment
Participants0.25mg DRSP / 0.5mg E2 (BAY86-4891)0.5mg NETA / 1.0mg E2 (Activella)
Number of Participants With Amenorrhea During Month 1 to 3 of Treatment25567
Statistical analysis
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) · Proportion: 0.687 · 95% CI 0.637 to 0.734
  • 0.5mg NETA / 1.0mg E2 (Activella) · Proportion: 0.593 · 95% CI 0.496 to 0.684
SecondaryNumber of Participants With Amenorrhea During Month 10 to 12 of Treatment

The women were to record any bleeding daily in a diary, indicating 'no bleeding', 'spotting', 'light bleeding', 'normal bleeding' or 'heavy bleeding'. Women were considered to have amenorrhea if they had no bleeding and no spotting day within the given time interval.

Time frame:
Month 10 to Month 12
Reported as:
Number · Participants
Number of Participants With Amenorrhea During Month 10 to 12 of Treatment
Participants0.25mg DRSP / 0.5mg E2 (BAY86-4891)0.5mg NETA / 1.0mg E2 (Activella)
Number of Participants With Amenorrhea During Month 10 to 12 of Treatment28089
Statistical analysis
  • 0.25mg DRSP / 0.5mg E2 (BAY86-4891) · Proportion: 0.789 · 95% CI 0.743 to 0.830
  • 0.5mg NETA / 1.0mg E2 (Activella) · Proportion: 0.840 · 95% CI 0.756 to 0.904

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.25mg DRSP / 0.5mg E2 (BAY86-4891)—16/489 (3.3%)172/489 (35.2%)
0.5mg NETA / 1.0mg E2 (Activella)—6/172 (3.5%)63/172 (36.6%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
Event0.25mg DRSP / 0.5mg E2 (BAY86-4891)0.5mg NETA / 1.0mg E2 (Activella)
Deafness neurosensoryEar and labyrinth disorders0/4891/172
HyperparathyroidismEndocrine disorders0/4891/172
Retinal vascular thrombosisEye disorders0/4891/172
AppendicitisInfections and infestations0/4891/172
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4891/172
Grand mal convulsionNervous system disorders0/4891/172
LymphadenopathyBlood and lymphatic system disorders1/4890/172
Abdominal pain lowerGastrointestinal disorders1/4890/172
ConstipationGastrointestinal disorders1/4890/172
FaecalomaGastrointestinal disorders1/4890/172
Most frequent other events
Showing 10 of 16
Most frequent other events
Event0.25mg DRSP / 0.5mg E2 (BAY86-4891)0.5mg NETA / 1.0mg E2 (Activella)
HeadacheNervous system disorders32/4897/172
Breast painReproductive system and breast disorders21/48910/172
Postmenopausal haemorrhageReproductive system and breast disorders14/4899/172
InfluenzaInfections and infestations21/4896/172
Cervical dysplasiaReproductive system and breast disorders11/4897/172
NasopharyngitisInfections and infestations18/4892/172
DepressionPsychiatric disorders9/4896/172
Weight increasedInvestigations17/4893/172
Back painMusculoskeletal and connective tissue disorders17/4892/172
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)16/4894/172

Baseline characteristics

Age, Continuous
Age, Continuous(Years)0.25mg DRSP / 0.5mg E2 (BAY86-4891)0.5mg NETA / 1.0mg E2 (Activella)Total
Mean53.5 ± 5.153.5 ± 4.553.5 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)0.25mg DRSP / 0.5mg E2 (BAY86-4891)0.5mg NETA / 1.0mg E2 (Activella)Total
Female489172661
Male000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)0.25mg DRSP / 0.5mg E2 (BAY86-4891)0.5mg NETA / 1.0mg E2 (Activella)Total
Mean26.315 ± 4.85126.020 ± 5.47626.184 ± 5.008
Number of participants with hysterectomy/oophorectomy
Number of participants with hysterectomy/oophorectomy(Participants)0.25mg DRSP / 0.5mg E2 (BAY86-4891)0.5mg NETA / 1.0mg E2 (Activella)Total
Hysterectomized000
Oophorectomized25530
Years since last menstruation at baseline
Years since last menstruation at baseline(years)0.25mg DRSP / 0.5mg E2 (BAY86-4891)0.5mg NETA / 1.0mg E2 (Activella)Total
Mean5.109 ± 4.5284.807 ± 4.2875.031 ± 4.465
08

Study locations

59 sites
  • Chandler, Arizona 85224, United States
  • San Diego, California 92103, United States
  • San Diego, California 92108, United States
  • Denver, Colorado 80218, United States
  • Greenwood Village, Colorado 80111, United States
  • Boynton Beach, Florida 33437, United States
  • Clearwater, Florida 33759, United States
  • Boise, Idaho 83704, United States
  • Amite, Louisiana 70422, United States
  • Marrero, Louisiana 70072, United States
  • Las Vegas, Nevada 89122, United States
  • Cleveland, Ohio 44122, United States
  • Philadelphia, Pennsylvania 19114, United States
  • Columbia, South Carolina 29201, United States
  • Corpus Christi, Texas 78414, United States
  • Richmond, Virginia 23294, United States
  • Seattle, Washington 98105, United States
  • Lanus Oeste, Buenos Aires 1824, Argentina
  • San Isidro, Buenos Aires B1642CLN, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1117ABH, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1280AEB, Argentina
  • Mödling, Niederösterreich 2340, Austria
  • Wiener Neustadt, Niederösterreich 2700, Austria
  • Fuerstenfeld, Steiermark 8280, Austria
  • Wörgl, Tirol 6300, Austria
  • Bregenz, Vorarlberg 6900, Austria
  • Innsbruck, 6020, Austria
  • Klagenfurt, 9020, Austria
  • Mürzzuschlag, 8680, Austria
  • St. Poelten, 3100, Austria
  • Wien, 1030, Austria
  • Wien, 1060, Austria
  • Wien, 1090, Austria
  • Wien, 1200, Austria
  • Zeltweg, 8740, Austria
  • Goiania, Goiás 74175-080, Brazil
  • Curitiba, Parana 80030-220, Brazil
  • Porto Alegre, Rio Grande do Sul 90035-001, Brazil
  • Sao Paulo, 04062-003, Brazil
  • Alborg, 9000, Denmark
  • Ballerup, 2750, Denmark
  • Vejle, 7100, Denmark
  • Bologna, 40138, Italy
  • Cagliari, 09124, Italy
  • Modena, 41124, Italy
  • Novara, 28100, Italy
  • Parma, 43100, Italy
  • Pisa, 56126, Italy
  • Sassari, 07100, Italy
  • Siena, 53100, Italy
  • Mexico, Distrito Federal, Mexico
  • Mexico, 06700, Mexico
  • Monterrey, 64460, Mexico
  • México, D.F., 14050, Mexico
  • Moscow, 117415, Russian Federation
  • Moscow, 177997, Russian Federation
  • Moskva, 101000, Russian Federation
  • Moskva, 113093, Russian Federation
  • Moskva, 117997, Russian Federation
09

References and documents

Publications

  • Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17beta-estradiol in postmenopausal women. Climacteric. 2013 Aug;16(4):490-8. doi: 10.3109/13697137.2013.783797. Epub 2013 May 11. PubMed 23531117 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 2 years 10 months after primary completion. A results delay was requested in Sep 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2007
First posted
Aug 30, 2007
Start
Aug 2007
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results delay requested
Sep 21, 2010
Results first posted
Jun 28, 2012
Last update
Dec 31, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00522873
Lead sponsor
Bayer
Collaborators
Laboratorium für Klinische Forschung, Diagnostic Cytology Laboratory, University of California, San Francisco
Responsible party
Sponsor
First posted
Aug 30, 2007
Start date
Aug 2007
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Jun 28, 2012
Last update
Dec 31, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Drospirenone · Estradiol

Start the discussion